An observational study in Fatty Liver Disease, sponsored by Beijing Tsinghua Chang Gung Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-16.
Sponsored by Beijing Tsinghua Chang Gung Hospital · Observational
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.
2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 167 across 681 observational studies indexed under Liver Diseases.
Browse Liver Diseases studies →Beijing Tsinghua Chang Gung Hospital is the lead sponsor of 96 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
adults with health check-ups at multiple health examination centers across China.
Exclusion Criteria:
Adults with health check-ups at multiple health examination centers across China
Diagnostic Test: Fibrotouch
Fibrotouch will be performed showing the stiffness and fat content of liver
To investigate the prevalence of MAFLD among adults at multiple health examination centers across China.
MAFLD means metabolic dysfunction-associated fatty liver disease
Time frame: through study completion, an average of 1 year
To assess the proportion of overweight or obese patients with MAFLD (BMI≥23 kg/m²).
MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index
Time frame: through study completion, an average of 1 year
To assess the prevalence of metabolic dysfunction among patients with MAFLD who are lean or normal in body weight (BMI < 23 kg/m²)
MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index
Time frame: through study completion, an average of 1 year
To assess the prevalence of type 2 diabetes among patients with MAFLD.
MAFLD means metabolic dysfunction-associated fatty liver disease
Time frame: through study completion, an average of 1 year
To assess the prevalence of liver fibrosis and cirrhosis among patients with MAFLD.
MAFLD means metabolic dysfunction-associated fatty liver disease
Time frame: through study completion, an average of 1 year
Plan to share: Undecided — Not yet determined
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Tsinghua Chang Gung Hospital